N-Butyldeoxynojirimycin (hydrochloride) – 1 mg

Brand:
Cayman
CAS:
210110-90-0
Storage:
-20
UN-No:
Non-Hazardous - /

N-Butyldeoxynojirimycin (NB-DNJ) is an iminosugar that inhibits ceramide-specific glucosyltransferase and β-glucosidase 2 (IC50s = 32 and 81 μM, respectively, for rat recombinant enzymes).{38202} The addition of NB-DNJ to growth medium for COS-7 cells expressing wild-type, S364R, N370S, V15M, or M123T glucocerebrosidase, an enzyme deficient in Spanish populations with the sphingolipid storage disorder Gaucher disease, leads to a 2.1-, 1.3-, 2.3-, 3.6,- or 9.9-fold increase in enzyme activity.{38203} NB-DNJ also inhibits HIV-1 and HIV-2 infection of peripheral blood mononuclear cells (PBMCs) with IC50 values of 282 and 211 μM, respectively.{38204} Formulations containing NB-DNJ have been used for the treatment of Gaucher disease and juvenile Sandhoff disease.{38205}  

 

Out of stock

SKU: 21065 - Category:

Description

An inhibitor of ceramide-specific glucosyltransferase and β-glucosidase 2 (IC50s = 32 and 81 μM, respectively, for rat recombinant enzymes); leads to a 2.1-, 1.3-, 2.3-, 3.6,- and 9.9-fold increase in the activity of wild-type, S364R, N370S, V15M, and M123t glucocerebrosidase in COS-7 cells; inhibits HIV-1 and HIV-2 infection of PBMCs (IC50s = 282 and 211 μM, respectively) ,


Formal name: 1-butyl-2R-(hydroxymethyl)-3R,4R,5S-piperidinetriol, monohydrochloride

Synonyms:  Miglustat|NB-DNJ

Molecular weight: 255.7

CAS: 210110-90-0

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Small Molecule Inhibitors|Sphingolipid Turnover||Research Area|Endocrinology & Metabolism|Carbohydrate Metabolism||Research Area|Immunology & Inflammation||Research Area|Infectious Disease|Viral Diseases|HIV & AIDS||Research Area|Lipid Biochemistry|Sphingolipids